Taking Stock 

Big pharma stymied by slump in non-Covid-19 treatments

Mark Robinson

Big pharma stymied by slump in non-Covid-19 treatments

The clinical outlook may have brightened now that Pfizer (US: PFE) has revealed that its Covid-19 vaccine achieved an efficacy rate upwards of 90 per cent in recent international trials, but it is probable that the virus will continue to have both direct and indirect impacts for the wider healthcare industry for some time to come, a point borne out by contrasting quarterly trading updates for GlaxoSmithKline (GSK) and AstraZeneca (AZN).

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now